FFA
SAGE

Farther Finance Advisors’s Sage Therapeutics SAGE Stock Holding History

Farther Finance Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25
Closed -$136 – 4404
2024
Q4 		$136 Hold
25
– – ﹤0.01% 3735
2024
Q3 		$181 Hold
25
– – ﹤0.01% 3679
2024
Q2 		$276 Buy
25
+14
+127% +$179 ﹤0.01% 3423
2024
Q1 		$197 Hold
11
– – ﹤0.01% 3278
2023
Q4 		$238 Buy
11
+4
+57% +$79 ﹤0.01% 3191
2023
Q3 		$144 Buy
+7
New +$202 ﹤0.01% 2512

Other funds holding SAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Farther Finance Advisors's SAGE Position: Q1 2025 in Review

Farther Finance Advisors sold out of Sage Therapeutics (SAGE) in Q1 2025, closing a stake of 25 shares — an estimated $136 sold.

Farther Finance Advisors first reported a position in SAGE in Q3 2023 and held it in 6 quarters. The position peaked at $276 in Q2 2024. 198 funds tracked by Wall St. Rank hold SAGE as of Q1 2025.

  • Farther Finance Advisors reported no remaining Sage Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Farther Finance Advisors sold 25 Sage Therapeutics shares in Q1 2025, an estimated $136.
  • Farther Finance Advisors first reported a position in Sage Therapeutics in Q3 2023 and held it in 6 quarters.
  • Farther Finance Advisors's Sage Therapeutics position peaked at $276 in Q2 2024.
  • 198 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2025.

Based on Farther Finance Advisors's 13F filing for Q1 2025, filed 14 Apr 2025.